VIVES is a multi-sector fund that invests in projects with a positive societal impact
ViroVet is a pioneering company dedicated to the development of innovative and disruptive technologies for the control of viral diseases in livestock. It develops antiviral drugs for complex...
ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses. It is...
Axinesis is a spin-off of the Université catholique de Louvain (Belgium), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
LMO (Luxembourg & UK) and In-Space Missions Ltd (UK) have partnered to explore the use of small satellite platforms for space-based Space Domain Awareness (SDA) as part of LMO’s AUREA (Autonomous
New funding will support the rapid growth of Aphea.Bio, solidifying its position as a frontrunner in biological product development for agriculture.
Gent, Belgium, 11 July 2023 – Aphea.Bio, a Belgium